Stem Cell Therapy: A New Treatment for Burns? by Arno, Anna et al.






Stem Cell Therapy: A New Treatment for Burns? 
Anna Arno 1,2, Alexandra H. Smith 1, Patrick H. Blit 1, Mohammed Al Shehab 1,  
Gerd G. Gauglitz 3 and Marc G. Jeschke 1,* 
1 Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, University of Toronto,  
2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada 
2 Plastic Surgery Department and Burn Unit, Vall d’Hebron University Hospital, Autonomous 
University of Barcelona, Passeig de la Vall d’Hebron 119-129, 08035, Barcelona, Spain 
3 Department of Dermatology and Allergology, Ludwig Maximilians University,  
Geschwister-Scholl-Platz 1, 80539, Munich, Germany 
* Author to whom correspondence should be addressed: E-Mail: marc.jeschke@sunnybrook.ca;  
Tel.: +1-416-480-6703; Fax: +1-416-480-6763. 
Received: 12 July 2011; in revised form: 21 September 2011 / Accepted: 10 October 2011 /  
Published: 21 October 2011 
 
Abstract: Stem cell therapy has emerged as a promising new approach in almost every 
medicine specialty. This vast, heterogeneous family of cells are now both naturally 
(embryonic and adult stem cells) or artificially obtained (induced pluripotent stem cells or 
iPSCs) and their fates have become increasingly controllable, thanks to ongoing research in 
this passionate new field. We are at the beginning of a new era in medicine, with multiple 
applications for stem cell therapy, not only as a monotherapy, but also as an adjunct to other 
strategies, such as organ transplantation or standard drug treatment. Regrettably, serious 
preclinical concerns remain and differentiation, cell fusion, senescence and signalling 
crosstalk with growth factors and biomaterials are still challenges for this promising 
multidisciplinary therapeutic modality. Severe burns have several indications for stem cell 
therapy, including enhancement of wound healing, replacement of damaged skin and perfect 
skin regeneration – incorporating skin appendages and reduced fibrosis –, as well as systemic 
effects, such as inflammation, hypermetabolism and immunosuppression. The aim of this 
review is to describe well established characteristics of stem cells and to delineate new 
advances in the stem cell field, in the context of burn injury and wound healing. 
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Burn injury is a devastating trauma with systemic consequences. Although survival rates are 
increasing, burn injury remains a great challenge in the field of cutaneous wound healing. Major burn 
patients lack enough skin to cover their burns and the currently used cutaneous substitutes and cultured 
epithelial autografts (CEA) are still neither efficient nor effective solutions [1,2]. Transplanted skin 
from donors is currently not an option due to rejection; however, augmenting immunotolerance via 
stem cell therapy may overcome this problem. Regenerative medicine using stem cells (SC) is an 
efficient, low-morbidity and high-quality therapy for skin coverage in burns, mainly due to the 
regeneration of skin appendages [3] and the minimal risk of hypertrophic scarring [4]. Furthermore, 
stem cells may be able to address the other systemic effects of burn injury, such as hypermetabolism 
and inflammation [5]. Further research is needed to analyze long-term effects of SCs and unravel the 
optimal method of administration (when and with which matrix). 
2. Skin Regeneration 
Skin maintains homeostasis by temperature regulation via hair follicles, sweat glands and dermal 
capillaries, and by lubrication via sebaceous glands. Burn injury represents a cellular stress in the skin. 
Normal adult skin repair is slow, with high risk of infection and hypertrophic scarring [3]. Epidermal 
keratinocytes form a scar without cutaneous appendages, such as hair follicles, sweat or sebaceous 
glands (Table 1). The regenerated epidermis is thin and has fewer and flatter epidermal ridges. 
Table 1. Main differences between epidermis and dermis skin layers. 
SKIN 
LAYERS 
ORIGIN VASCULARITY CHARACTERISTICS MAIN 
CELLS 
EPIDERMIS Ectoderm Avascular Keratinized stratified epithelium Melanocytes 
Keratinocytes 






Superficial = Papillary  Highly vascular  
Lax 
Deep = Reticular  Less vascular 
Dense 
The epidermis contains no blood vessels, and is nourished by diffusion from the dermis. The main 
cell types that make up the epidermis are keratinocytes, melanocytes, Langerhans cells and Merkels 
cells. The dermis is basically composed of connective tissue and contains skin appendages. 
Stem cells exist in adult tissue on reserve to repair cells following stress signals [6]. The vast 
majority of skin stem cells are located in the hair follicle bulge [7]. To repair and reepithelialize a 
wound, stem cells from the hair follicle bulge give rise to daughter skin cells, which migrate to the 
epidermis (basal layer and sebaceous gland) [8] (Table 2). In adult skin, superficial burns that leave 
hair follicles intact are healed rapidly with the regeneration of epidermal appendages. Deeper injuries 
that affect the hair follicle bulge heal with a scar and without adnexal structures [3]. 
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Table 2. Types of cutaneous stem cells. 




Melanocytes MSC Neural Endothelial 
Interfollicular Hair 
Bulge 
Cutaneous stem cells include epidermal stem cells (interfollicular and bulge stem cells), dermal 
stem cells, sebaceous stem cells, hair follicle stem cells, sweat gland stem cells, melanocyte stem 
cells, mesenchymal stem cells, neural stem cells and endothelial stem cells. The more abundant 
skin stem cells are the epidermal hair bulge stem cells. Only a small fraction of stem cells, the 
interfollicular stem cells, reside in the basal layer of the interfollicular epidermis. These stem cells 
maintain adult skin homeostasis and hair regeneration, but they also participate in the repair of the 
epidermis after trauma. 
Regenerative medicine aims to not only accelerate reepithelialization after burn injury, but also to 
reconstruct functional skin with sweat glands, hair follicles and dermal capillaries. These goals might be 
achieved by stem cell therapy. Approaches to stem cell therapy include local recruitment of endogenous 
SCs or SC transplantation (often in vitro modified), either of which can be combined with gene therapy 
or tissue engineering. Tissue engineering is an experimental procedure that combines cellular biology, 
engineering and medicine to develop three-dimensional tissues and restore function [9]. 
3. Stem Cells Definition and Classification 
3.1. Stem Cells Definition 
Stem cells (SCs) are defined by two main characteristics: their capacity of prolonged self-renewal 
(proliferation) and multilineage differentiation (asymmetric replication) [3,10]. These characteristics are 
more pronounced in younger sources [11]. By asymmetric replication, after every cell division, one cell 
retains its self-renewing capacity, while the other (transit-amplifying or TA cell) enters a differentiation 
pathway and joins a mature non-dividing population [12]. When an unspecialized stem cell differentiates, it 
assumes characteristics of a specific tissue [13]. SCs are pluri-, multi- or unipotent [14]. The zygote is the 
only mammalian cell capable of producing all cells and tissues of an organism and thus is considered 
totipotent [15]. Pluripotent cells produce cells and tissues belonging to all three germ layers—
Ectoderm, mesoderm and endoderm [16]. Multipotent cells produce more than one cell lineage, within 
a closely related family of cells. Unipotent cells only differentiate into a single cell phenotype [17]. 
Plasticity describes the phenomenon whereby SCs from one tissue produce cell types of a completely 
different tissue [18]. SCs can remain undifferentiated, in which state there is risk of uncontrolled 
proliferation and tumor formation [11]. SCs have a slow-cycling nature in vivo, high proliferative 
potential and participate in tissue regeneration and repair, during both fetal development and adult 
wound healing [19]. 
3.2. Stem Cells Classification 
When classified by origin, there are two types of stem cells: embryonic (ESC) and non-embryonic 
stem cells. The latter are also referred to as adult (ASC) or somatic stem cells (however, SCs derived 
from the placenta or umbilical cord are also considered ASCs) [20,21]. Embryonic germ cells are 
Pharmaceuticals 2011, 4                  
          
 
1358
derived from the primitive gonadal ridges of the developing embryo or fetus (6-9 weeks gestation in 
the humans) and have many of the pluripotential properties of ESCs [22]. 
3.2.1. Embryonic Stem Cells (ESCs) 
ESCs are pluripotent stem cells derived from the inner cell mass of an early stage embryo known as 
blastocyst [10] and give rise to all cells of the three embryonic germ layers: endoderm, mesoderm  
and ectoderm. Human Embryonic Stem Cells (hESCs) are derived from excess developing  
pre-implantation embryos (5 day-old embryos, 4-8 day-old morula, or inner cell mass of blastocysts) 
that have usually been fertilized in vitro at a fertilization clinic. ESCs can be propagated indefinitely in 
an undifferentiated state [23] in vitro using either feeder layers or extracellular stimuli (e.g., cytokines 
or growth factors) [24]. Derivation of human embryonic cell lines is controversial because it requires 
destruction of an embryo [11], may develop teratocarcinomas (tumours composed of tissues from all 
three germ layers [25]), are immunogenic and show genetic instability in vitro [15]. Accordingly, adult 
stem cell research is currently favoured [6,26,27]. Apart from being used in regenerative medicine, 
ESCs may be used to perform developmental, genetic (through knock-out technology) and 
pharmacological research. hESC-based in vitro studies of drug toxicity have proven to be an accurate 
alternative to experimental animal models [28]. 
ESCs are capable of unlimited expansion in vitro and are considered an immortal epiblast derivative 
with a checkpoint in differentiation that enables their expansion as undifferentiated colonies, which 
can be instructed to maintain this phenotype indefinitely [23]. 
3.2.2. Adult Stem Cells (ASCs) 
SC clinical studies have increased during the past two decades in almost every field of medicine; 
including, haemato/immunotherapies [29-32], diabetes mellitus [33], chronic degenerative illnesses 
(e.g., in the field of rheumatology) [34-37], cardiovascular diseases [38], multiple sclerosis and other 
neuropathies [39], corneal repair [40] and wound healing [41]. 
Adult stem cells (ASCs) were discovered in the mid-1950s; they are found in low abundance in 
almost all adult tissues and in high abundance in the umbilical cord [10]. They are found in special 
regulatory niches as self-renewing progenitor cells that are able to produce one or more specialized cell 
types. ASCs are usually considered to be tissue specific, self-renewing populations of cells, which can 
differentiate into cell types associated with the organ system in which they reside [42]. 
Slowly replicating and bromodeoxyuridine-label-retaining, ASCs are under strict regulatory control 
of their mobilization and differentiation [23]. ASCs are less potent (usually only uni- or multipotent) 
and have less differentiation potential than ESCs. Distinct from ESCs, ASCs are not capable of 
unlimited expansion in vitro. ASC potency and plasticity is still in contention, though [11,22,43]. 
ASCs include mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), epithelial and 
neural stem cells, and others. HSCs and MSCs originate in the bone marrow (MSCs may have 
additional origins, as we will describe later) and differentiate into endothelium, liver, bone, muscle, 
skin or others [11]. 
Epidermal and dermal SCs are also multipotent. It has been suggested that they not only contribute 
to skin production, but can also be stimulated into neural and osteogenic lineages [44,45]. 
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3.2.3. Induced Pluripotent Stem Cells (iPSCs) 
Induced pluripotent stem cells (iPSCs) are artificially derived from non-pluripotent cells, typically 
adult somatic cells (mostly fibroblasts of murine or human origin), most frequently by epigenetic 
reprogramming and also by nuclear transfer or cell division [46]. Expression of transcription  
factors characteristic for undifferentiated embryonic stem cells is induced; for example, OCT4 (also 
known as POU5F1, being the most important one), SOX2, c-MYC, KLF4, Lin28 and/or  
NANOG [6,10,15,47,48] (Figure 1). Transcription factors or cell markers are the key mediators of 
cellular identity [49]. Direct reprogramming (also referred to as transdifferentiation) describes ectopic 
expression of defined transcription factors, a very slow and inefficient process that may limit the quality 
of resulting iPSCs [50]. For example, fibroblasts can be reprogrammed into neurons, cardiomyocytes and 
blood-cell progenitors [51-53]. Small molecules may improve the reprogramming efficiency but increase 
its tumorigenicity [54]. Elements that influence reprogramming include the respective donor cell type, 
the transcription or reprogramming factors utilized, the mode of delivery (e.g., virus, RNA, etc.) and the 
culture conditions, all of which depend on the purpose of the process [46]. 
Figure 1. Methods of production of induced pluripotent stem cells. Reproduced from [10] 
with permission from Rightslink. 
 
iPSCs are generated from adult somatic cells through somatic cell nuclear transfer (SCNT), cell 
fusion or direct reprogramming, by ectopic expression of defined transcription factors. iPSCs are 
pluripotent stem cell lines suitable for disease modeling, autologous cell therapy, drug screening 
and basic research. 
Broadly, we could imagine iPSCs as “artificial ESCs”. iPSCs represent stable lines of embryonic-like 
pluripotent stem cells [55]. In contrast to ESCs, human iPSCs can be derived from the patient to be 
treated (for autologous cell therapy), reducing the risk of HLA mismatching and immune rejection [56]. 
iPSCs may also be used for establishing in vitro disease models, drug or toxicity screening, and basic 
gene research [46]. iPSCs represent a widely available, non-controversial, non-restricted and practically 
infinite source of pluripotent cells. Nonetheless, they still share with classic ESCs the critical 
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disadvantage of malignancy transformation [10]; although, integrative delivery systems with consequent 
deletion seems to lower the risks of iPSCs oncogenesis [54]. A multitude of protocols for iPSCs 
generation have been developed in recent years, spanning across different mouse and human donor 
populations and varying in the number, identity and delivery of the reprogramming factors [57-60]. 
4. Adult Mesenchymal Stem Cells 
Ideally, stem cells for regenerative medicine should be abundantly available, accessible by a 
minimally invasive procedure and then safely and effectively transplanted to either an autologous or 
allogeneic host [6]. As previously mentioned, tumorigenicity and ethical considerations have impeded 
the widespread clinical use of ESCs [11]. Instead, most regenerative medicine research is focused on 
iPSCs and ASCs; in particular, adult mesenchymal stem cells (MSCs) [61,62]. 
MSCs are derived mainly from bone marrow and adipose tissue [63,64], and to a lesser extent, 
placenta [65], amniotic fluid [61], umbilical cord [66], dental pulp [67], tendon [68], trabecular bone [69] 
and synovia [70]. Actually, MSCs may reside in all post-natal tissues. Bone marrow (where they were 
first identified) and adipose tissue are the main sources of MSCs for cell therapy, due to high 
expansion potential and reproducible isolation protocols [71]. CD34+ hematopoietic stem cells are the 
most widely studied and represent the only currently clinically approved stem cell [12,71].  
Human mesenchymal stem cells (hMSCs) are characterized by three criteria: (1) plastic-adherent 
under culture; (2) capacity to differentiate into at least three mesenchymal lineages: bone, fat and 
cartilage; (3) express cell markers CD73, CD90, CD105 and negative for CD11b, CD14, CD34, CD45 
and HLA-DR [62,72].  
MSCs release various cytokines and growth factors that influence the microenvironment by either 
modulating the host immune response or stimulating resident cells [73], conferring anti-fibrotic,  
anti-apoptotic, pro-angiogenic and immunosuppressive properties [74,75]. Mediators involved in 
MSC-mediated immunomodulation include interferon-, toll like receptors, tumor necrosis factor-, 
interleukin (IL)-1, IL-1, indoleamine 2,3-dioxygenase, leukemia inhibitory factor, HLAG5, IL-10, 
transforming growth factor (TGF)-1, hepatocyte growth factor, heme oxygenase1, IL6, IL-1 receptor 
antagonist (IL-1RA) and prostaglandin E2 [71,75-80]. MSCs also stimulate the proliferation of other 
progenitor cell populations within target organs to promote endogenous repair [77]. 
MSCs have a great potential in tissue engineering and may serve to treat chronic inflammatory and 
degenerative disorders due to their immunosuppressive properties [75,81]. They are currently being 
tested in several clinical trials for osteoarthritis, osteogenesis imperfecta, articular cartilage defects, 
osteonecrosis and bone fracture [82,83]. They are considered ‘immunoprivileged’ by many researchers 
and may permit allo-transplantation without immunosuppressive therapy, which would become 
particularly useful in treating acute injuries [84,85]. Having said that, animal studies have shown that 
intramyocardial injection of MSCs may differentiate into encapsulated structures with calcifications 
and ossifications, raising the possibility of malignant transformation [77]. 
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5. Main Sources of Adult Stem Cells 
5.1. Bone Marrow-Derived Stem Cells (BMSCS) 
Bone marrow has been the primary source of mesenchymal stem cells; however, bone marrow 
collection is invasive and MSC isolation is inefficient (<0.05%) [86,87]. BMSCs are able to undergo cell 
fusion, a natural process of mingling of genetic material that modifies gene expression patterns [88]. Cell 
fusion is implicated in regeneration, normal development, immune response and tissue formation and 
plays a prominent role in stem cell plasticity [89]. Indeed, cell fusion can modify the gene program and 
govern cell fate, transforming the cell into a more immature state to achieve a regenerative function [90]. 
Haematopoietic stem cell transplantation is the first and most widely available stem cell therapy [91]. 
hMSCs derived from bone marrow are capable of differentiating into epithelial cells of the liver, lung, 
gastrointestinal tract and skin [92]. 
Autologous bone-marrow derived cultured hMSCs have been applied to wounds, using a 
specialized fibrin spray system; this approach is currently being performed and supposed to be safe and 
valid for topical cell administration, although with no solid data to support its validity [93]. 
5.2. Adipose Tissue-Derived Stem Cells (ADSCS) 
Adipose-derived stem/stromal cells (ADSCs) are multipotent somatic stem cells that can 
differentiate into several lineages, including adipose cells, chondrocytes, osteoblasts, endothelial cells, 
epithelium, cardiomyocytes and neuronal cells [94]. The existence of stem cells within adipose tissue 
was reported for the first time in 2001 [95]. They are often described as processed lipoaspirate cells 
(PLA), preadipocytes, or adipose stem cells, although the international Fat Applied Technology 
Society recommends the term “ADSCs” [6]. ADSCs express mesenchymal cell-specific markers and 
molecular markers typical for the embryonic stem cell phenotype: OCT4, Nanog and Sox2 [96,97]. 
ADSCs are heterogeneous, differing depending on their anatomical regions and depending on their 
type (white or brown) [98]. 
Current research suggests that they may actually be pluripotent and form cell types of all three germ 
layers [99]. ADSCs represent a promising source of adult mesenchymal stem cells, mainly because 
isolation is less invasive and more efficient [6,71]. Aspirated fat is in plentiful supply in many plastic 
surgery procedures—e.g., liposuction and liposculpture—and precursor cells can be purified to obtain 
the ADSC-rich stromal vascular fraction (SVF) [100]. The SVF is a heterogeneous mixture containing 
endothelial cells, preadipocytes, fibroblasts, vascular cells, macrophages, and numerous mesenchymal 
stem cells [6] and is now studied as a supplement to free fat transfer in order to increase yield [101]. 
Expansion of ADSC populations in culture can yield 100 to 1,000 times more progenitor cells than 
isolation from bone marrow [102]. 
Besides being one of the richest sources of ASCs in the human body, adipose tissue is also an 
endocrine organ that secretes numerous hormones, growth factors and cytokines, that support wound 
healing and other functions such as leptin, epidermal growth factor, tumor necrosis factor-, basic 
fibroblast growth factor, keratinocyte growth factor, transforming growth factor-1 (TGF-1), vascular 
endothelial growth factor, hepatocyte growth factor, interleukin (IL)-6, IL-7, IL-8, IL-11, IL-12, 
macrophage-colony stimulation factor, platelet-derived growth factor, brain-derived neurotrophic 
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factor, granulocyte colony stimulating factor and leukaemia inhibitory factor [6,102]. These paracrine 
influences are of great importance in many stem cell therapies, creating a favourable environment for 
development of more functional cells and tissue repair, through promotion of neovascularization, 
endogene repair mechanisms and regulation of immune responses [77,103]. 
ADSCs represent a highly efficient source of iPSCs [104]. They may be used to test drug toxicity, 
reducing the need for animals. They may also offer an important tool for cell-based gene therapy in the 
field of wound healing, because ADSCs can efficiently (above 60%) be transducted with vectors [12,105].  
Various clinical trials have shown the regenerative capability of adipose-derived stem cells in 
subspecialties of medical fields such as plastic surgery (for breast reconstruction and aesthetic 
lipofilling), general surgery (to heal chronic fistulas in Crohn’s disease), orthopedic surgery, oral and 
maxillofacial surgery (to stimulate bone repair in calvarial defects) and cardiology (ischemic heart 
disease and acute myocardial infarct) [77,106,107]. With the risk of malignancy transformation and 
heterogeneity, however, there is still not enough evidence to encourage wide and safe use of ADSCs 
and further research is required [108-110]. Future studies to optimize the differentiation of ADSCs into 
deficit cells may unlock their therapeutic potential in regenerative medicine. 
All in all, ADSCs hold great promise for use in tissue repair and regeneration, due to their availability, 
pro-angiogenic an anti-apoptotic factor secretion, immunomodulatory effects and multilineage 
differentiation, becoming one of the most popular adult stem cells currently explored [6,77,100,103,111]. 
5.3. Umbilical Cord (Blood) Derived Stem Cells 
Umbilical cord (UC) and cord blood-derived stem cells remain the world’s largest potential source 
of stem cells, considering the global birth rate of around 135 million per year [86]. The umbilical cord 
represents a well known source of endothelial progenitor cells [112]. Umbilical cord blood contains 
haematopoietic as well as non-haematopoietic stem cells, these latter also named as CBEs (Cord Blood 
Embryonic-like stem cells) [113,114]. CBEs have been shown to differentiate into neural, 
hepatobiliary, pancreatic-like precursors and potentially others [115,116].  
Human umbilical cord blood is a rich source of hemopoietic stem cells for clinical application and 
may be one of the largest sources of stem cells with naive immune status [12,101].  
From innermost to outermost, the layers within the UC include the vessels, Wharton’s jelly or matrix, 
and amniotic membrane or cord-lining, epithelium or subamnion [86]. Wharton’s jelly gives rise to 
MSCs and has lower cell density, yet allows us to quickly isolate many cells [117]. A single piece of  
5–10 mm3 of Wharton’s jelly has the potential to yield up to 1 billion MSCs in 30 days; bearing in mind 
that the average UC measures 50 cm [15], it undoubtedly represents a rich source of SCs. Human 
umbilical cord perivascular cells are nearly identical to Wharton’s jelly MSCs [118] (Figure 2). 
Amniotic membrane and cord-lining are sometimes interchangeable words referring to the UC 
membrane in general, or referring to different cell types. The outer membrane of the UC is an 
extremely rich source of stem cells for burn resurfacing [12]. The cord lining gives rise to multipotent 
epithelial stem cells (CL-epithelial stem cells) [86]. 
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Figure 2. The anatomy of the umbilical cord. Reproduced from [10] with permission from 
Rightslink. 
 
The umbilical cord contains vessels (two arteries and one vein), Wharton’s jelly and the  
outer membrane. 
Cord lining-mesenchymal stem cells (CL-MSC) express CD23, CD14 and low amounts of CD34 
and CD35; they do not express endothelial marker CD31 and have greater in vitro expansion than 
Wharton’s jelly-derived MSCs [119]. CD14 inhibits T cells. Wharton’s jelly derived MSCs do not 
express CD14 or CD23. Despite those descriptions, the cell markers of umbilical cord-derived MSCs 
are under great debate [86,120] (Figure 3). 
Figure 3. Photomicrographs of cord lining-epithelial cells (A) and cord lining-mesenchymal 
cells (B). Reproduced from [12] with permission from Righstlink. 
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Generally, umbilical cord-derived MSCs can differentiate into bone, skin, endothelium, hepatocyte, 
neural lineages and others. Amniotic membrane-derived MSCs specifically can differentiate into bone, 
cartilage and fat [12,121]. 
Regarding hematologic diseases, the immaturity of umbilical cord blood (UCB) cells is associated 
with low immunogenicity, which reduces their graft-versus-host reactivity compared to adult-derived 
bone marrow grafts [122]. On the other hand, umbilical cord blood supplies multipotent stem cells at a 
rate 30% lower than that achieved from adult bone marrow [101]. Umbilical cord blood was 
introduced as an alternative source of allogeneic HSCs after the success of cord transplantation in a 
child with Fanconi’s anemia. Both cord blood transplants and matched unrelated bone marrow 
transplants share similar disease-free survival and transplant-related mortality [91]. Further research 
will need to clarify when allogeneic cord blood transplantation is best indicated [124]. 
With respect to burns and skin wound healing, umbilical cord and amniotic membrane may emerge 
as new promising sources of “off-the-shelf” cell-engineered skin [86]. Moreover, co-administration of 
several types of stem cells may elicit synergistic benefits [77], suggesting the use of both epithelial and 
mesenchymal stem cells. 
5.4. Hair-Follicle Stem Cells 
Hair follicles are a promising source of easily accessible multi (or pluri) potent stem cells which are 
non-oncogenic and carry no ethical concerns, in contrast to embryonic stem cells or induced 
pluripotent stem cells. In fact, many researchers consider hair follicles to be the most promising source 
of multipotent stem cells [19,124]. 
Hair follicle pluripotent stem cells of the scalp are positive for nestin and the embryonic stem cell 
transcription factors Nanog and Oct4. These cells can differentiate into neurons, smooth muscle cells 
and melanocytes [125]. The hair follicle bulge area contains nestin-negative, K15-positive cells; these 
cells can differentiate into keratinocytes, neurons, glial cells and smooth muscle cells [126]. 
Human hair follicle stem cells promote nerve repair or the functional recovery of injured peripheral 
nerve and spinal cord [127]. 
Hair follicle bulge stem cells give rise to both hair follicle cells and epidermal cells. The hair 
follicle stem cells form epidermal stem cells only when the epidermis is wounded or stressed [128]. 
Bulge stem cells respond rapidly to epidermal wounding by generating short-lived TA cells 
responsible for acute wound repair [129] (Figure 4). Intense research is devoted to this promising 
source of stem-cell therapy to improve wound healing. 
6. Directing Cell Fate for Regenerative Medicine 
Regenerative medicine or cell-replacement therapy aims to treat human diseases caused by deficits 
in quality or quantity of particular cells, restoring damaged tissues in addition to alleviating the related 
symptoms. These diseases include neurodegenerative disorders, diabetes, liver and cardiovascular 
diseases, blindness, deafness, burns, and many others [130,131]. 
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Figure 4. Hair follicle bulge and multipotent stem cells. Reproduced from [19] with 
permission from Wolters Kluwer. 
 
Schematic representation of the cutaneous epithelium and the cell lineages derived from  
multi-potent stem cells in the hair follicle bulge. Under steady-state conditions, the stem cells are 
quiescent. At the beginning of the hair cycle when the lower follicle and matrix is regenerated, the 
stem cells in the bulge proliferate to give rise to new hair follicle keratinocytes. Under wounding 
conditions, the stem cells produce daughter cells that migrate from the niche to re-populate the 
basal layer of the epidermis, and the sebaceous gland. 
To accomplish its goal, regenerative medicine should be able to not only create these cells, but also 
to deliver them to patients. To create them, we can direct the cell fate of already available cells (ideally 
the patient’s own cells, although age and comorbidities impair stem cell functionality [12,77]). 
There are two main approaches to direct cell fate: (1) through directed differentiation, whereby 
cultured pluripotent stem cells (e.g., ESCs or iPSCs) follow several steps as they would in vivo or 
during embryonic development; or (2) via reprogramming or transdifferentiation, whereby a 
differentiated cell is converted directly into the cell of interest without proceeding through a 
pluripotent intermediate, most often by transcription factors [50,132-134]. 
Differentiation is performed in vitro by treating cells with recombinant growth factors (e.g., TGF- 
superfamily, WNT and fibroblast growth factors, combined with co-culture systems), or with small 
molecules, which are homogenous, stable chemical compounds that are non-immunogenic and cheaper 
than proteins [135,136]. In addition, differentiation can be accomplished through spontaneously with 
embryoid bodies or floating clumps of cells [50]. 
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Unfortunately, current protocols are still inefficient [137,138], but solutions for directed cell fate 
and transdifferentiation are under continuous investigation. 
7. Stem Cells and Burns 
Cell therapy has been used to treat burns since the introduction of composite epithelial autografts 
(CEA) by Green in 1975, evolving to dermal substitutes, later on to dermal-epidermal bio-engineered 
cultured skin substitutes and eventually to stem cells [139]. Stem cell therapy (allogeneic MSCs, iPSCs 
or immunomodulatory  TCells) after burn injury emerges as a promising treatment strategy, not only 
for wound healing, but also to treat systemic effects of burn trauma, the hypermetabolic response, 
inflammation (e.g., inflammatory-related diseases, such as acute lung injury/respiratory distress 
syndrome), and immunosuppression [5,140]. Stem cell therapy may offer an alternative to large volume 
resuscitation and be an adjunct to lung-protective ventilation strategies after severe burn injury [141]. 
Paracrine mechanisms and growth factor secretion, rather than post-engraftment differentiation and 
proliferation, seem to predominate in therapeutic effects of MSCs [71,139]. In vivo, MSCs attenuate 
proinflammatory cytokine release and nitric oxide production while upregulating the anti-inflammatory 
cytokines TGF-, IL-10 and IL-12 [5]. MSCs also exhibit antiapoptotic, immunosuppressive and 
antifibrotic effects [62]. 
For the treatment of acute and chronic non-healing wounds (not burn related), combined gene 
delivery with stem cell therapy appears promising [12]. Gene therapy involves the insertion of a gene 
into recipient cells by viral transfection, naked DNA application, high pressure injection or liposomal 
vectors [142]. Sequential growth factor gene therapy delivers a cocktail of growth factor genes at 
strategic time points of wound healing [12,143].  
To enhance the therapeutic response after stem cell treatment in burn patients, intense tissue 
engineering with the development of 3D scaffolds or matrices is of vital importance, as well as 
improved preconditioning cell treatments and optimized culture conditions [77]. 
7.1. The Challenge of Stem Cell Delivery in Burn Patients: A Link between Scaffolds and Wound Healing 
Stem cell administration for burn patients still remains a challenge of intense research [140]. 
Intravenous infusion and local application of MSCs have been described in the clinical setting [144]. The 
concomitant use of acellular matrices or scaffolds is strongly recommended in order to increase cell 
homing, differentiation, mobilization and adhesion, eventually improving wound healing [144,145]. 
An ideal method for the effective administration of stem cells for burn patients has not yet been 
elucidated. Further comparison of the local and systemic effects in burn patients associated with each 
route of stem cell delivery needs to be performed. There is still not enough evidence in terms of 
analyzing systemic or local effects of stem cell delivery in burn patients, regarding different possible 
routes of administration. We still do not know exactly which percentage of locally delivered cells in a 
burn wound exerts its effects in wound healing and which, if any, affects the main circulation and has 
systemic effects, regarding the inflammatory and hypermetabolic response after a major burn. On the 
other hand, the efficiency of non-topical administration (such as intrapulmonary infused cells primarily 
to treat adult respiratory distress syndrome) for wound healing is unclear. To help clarify this, reporter 
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gene imaging allows for stem cell tracking in vivo. Briefly, positron emission tomography is used to 
detect cell markers for assessment of the viability and location of stem cells after transplantation [146]. 
If we focus on wound healing, application of cells to the burn wound could be performed, either by 
the bedside as a non-invasive procedure, or in the operating room, immediately after debridement. The 
cells should be transferred on a matrix, scaffold or dermal substitute. One method is to first spray cells 
onto the wound with fibrin sealant [93] and afterwards cover with a dermal substitute, skin graft or 
film. The cover over the cells acts not only as a temporary dressing, but also to theoretically enhance 
cell paracrine signaling and homing of the cells, improving wound healing [147]. Although the use of 
cell administration using spray technologies is currently being performed in the clinical setting, there 
are no conclusive data to support its validity as a matrix vehicle.  
Cutaneous wound healing requires the well-orchestrated integration of cell migration and 
proliferation, as well as extracellular matrix deposition, angiogenesis, and remodelling [12]. Delays in 
burn wound closure worsen a patient’s susceptibility to infection, prolong pain, increase the total number 
of operative procedures, increase the incidence of hypertrophic scarring, and lengthen hospital stays. 
Stem cell therapies in wound care may lessen these morbidities [140]. Specifically, the burn wound has 
unique characteristics that have to be considered when designing a clinical trial for stem cell therapy 
applications: it is an ischemic wound, with an altered pH and temperature, prone to infection and 
development of chronic sequelae such as non-healing ulcers (sometimes even with malignant 
conversion) and hypertrophic scarring [148,149]. Furthermore, a major burn represents a handicap, with 
uncovered wounds open to air, which require frequent operations and dressing changes, and with long 
periods of immobilized hospital stay, which involve frequent position changes and physiotherapy, to 
avoid pressure sores, enhance rehabilitation and improve overall prognosis. This dynamic paradigm 
popularized the use of polymeric films for repair and closure of wounds. These films are semipermeable, 
microperforated and transparent materials that create an accelerated healing environment while avoiding 
dehydration, trauma and infection over the injury [150]. Additionally, radiofrequency applied to  
wound-contacting nano-engineered polymeric films (iron oxide-coated biodegradable nanoparticles 
and/or fibers -NPFs-) has been used to debride the wound. This may represent a novel burn treatment 
method, once stronger scientific evidence is available [151]. 
Several studies support the use of “intelligent matrices”, natural acellular matrices such as a porcine 
dermal acellular matrix accompanied by NPFs coated with monoclonal antibodies (e.g., anti-CD44) 
and loaded with specific growth factors, cytokines and antibiotics. The growth factors and cytokines 
improve the homing of autologous circulating MSCs, often elevated in patients with large burns [152], 
and also of delivered stem cells in general [144]. Chemoattractants for BM-MSC include hepatocyte 
growth factor, basic fibroblast growth factor and CXCL5, for instance [153]. Indeed, recruiting 
endogenous stem cells to the site of injury represents an alternative to transplantation; however, direct 
application of stem cells appears advantageous over diffusible growth factor administration. Stem cells 
can interact with their environment and release multiple wound healing factors [12]. Unfortunately, 
tissue-engineered dermal equivalents lack blood vessels and may act as possible barriers against 
nutrients necessary for keratinocyte or stem cell survival on top of such composites [144]. The time 
required to reperfuse the skin substitute increases the duration of ischemia, enhancing the risk of 
infection and graft destruction. One approach to minimize ischemia is through the use of BM-MSCs, 
which secrete VEGF [153]. On the other hand, VEGF could have detrimental effects in scarring [149]. 
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Furthermore, in severe burn trauma with sepsis, bone marrow suppression has been described.  
Ichoka et al. investigated the effect of a BM-MSC impregnated collagen matrix on wound healing in a 
microcirculatory mouse model and observed significant increases in angiogenesis [153]. Other models 
of delayed wound healing in diabetes also report stem cells stimulating wound healing. Fiorina et al. 
showed that bone-marrow progenitor cells BM/PCs mobilize to the site of injury during diabetic 
wound repair in db/db mice, where increased levels of stem cells corresponded to higher levels of 
wound reepithelialization [154]. 
Ha et al. showed that transplantation of BMSCs transfected with an adenovirus hepatic growth 
factor gene can accelerate wound repair in diabetic rats [155]. Tark et al. showed that human  
CB-MSCs improved wound healing, when applied to diabetic mice, probably due to TGF- [156].  
Promising preclinical results with stem cells in wound healing are encouraging further research. In 
2006, a patient bearing a diabetic foot was treated with a combination of autologous BM-MSCs and 
autologous fibroblasts on a biodegradable collagen membrane. Wound size decreased and vascularity 
increased [144]. Currently, nanoengineered multifunctional acellular biologic scaffolds, films and 
wound dressings emerge as delivery vehicles for stem cells in burn wounds. Although many types of 
tissue-regenerating stem cells may be used clinically, adding endometrial stem cells to MSCs may 
improve the vascularisation of these tissue engineered-constructs and significantly improve the 
outcomes of severely burned patients [144,145]. 
7.2. Legislation, Biosafety and Biotechnology Industry in Cell Therapy for Burn Care 
Stem cell research is in its early stages of development and the market is therefore still immature. 
Approximately 1.1 million people affected by burns and other wounds in the U.S. would benefit from 
cell therapy products [157]. Although the preliminary results achieved to date raise great expectations, 
many pharmaceutical companies are reluctant to enter this market. To date, the most profitable strategy 
has been the signing of agreements between big pharmaceutical and other small biotechnology 
companies whose activity is entirely devoted to cell therapy and regenerative medicine. In addition, 
many stem cell-derived products are developed at universities and basic research institutions, where 
preclinical studies are also conducted. 
Cell therapy, gene therapy and tissue engineering are considered ‘advanced therapy products’ 
(ATPs). As such, they should follow a regulatory framework to ensure patient accessibility and 
governmental assistance. An effective regulation implies scientific reality and objectivity, as well as 
flexibility to adapt as technology changes [159]. 
The U.S. Food and Drug Administration (F.D.A.) defines somatic cell therapy as the administration of 
autologous, allogeneic or xenogeneic non-germ cells excluding blood products for transfusion, which 
have been manipulated, processed, propagated, expanded, selected ex vivo, or drug-treated [160]. Cell 
therapy products are considered drugs, so they follow the same regulations, requiring a strict control of 
manipulation and facilities. Cell therapy products should adhere to the Current Good Manufacturing 
Practices, including quality control and quality assurance programs, which establish minimum quality 
requirements for management, staff, equipment, documentation, production, quality control,  
contracting-out, claims, product recall, and self-inspection [159]. The key points of the current FDA 
regulation for cell therapy products include: demonstrations of preclinical safety and efficacy; no risk for 
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donors of transmission of infectious or genetic diseases; no risk for recipients of contamination or other 
adverse effects of cells or sample processing; specific and detailed determination of the type of cells 
forming the product and what are their exact purity and potency; in vivo safety and efficacy of the 
product [161]. Cell therapy products must be carefully described, stating whether autologous, allogeneic 
or xenogeneic cells are administered. According to the U.S. F.D.A., human cells are considered 
xenogeneic cells provided there has been any ex vivo contact with living non-human cells, tissues or 
organs [160]. It should also be detailed whether cells have been manipulated together with biomaterials, 
growth factors or serum, which is common in burn applications. Indeed, the biomaterial itself may have a 
more important role than the cell product [159]. Biomaterials for cell therapy should be biocompatible to 
prevent immune rejection or necrosis, biodegradable and assimilable without causing an inflammatory 
response, and have certain structural and mechanical properties [162]. Whether natural or artificial, 
biomaterial type and use is related to the route of administration of cell therapy protocols, implantation or 
injection. In the latter, which are simpler, biomaterials are usually in a hydrogel state, forming a 
hydrophilic polymer network, as occurs in polyethylene oxide, polyvinyl alcohol, polyacrylic acid, 
agarose, alginate, collagen and hyaluronic acid. Control of the biomaterials’ porous structure is very 
important for increasing their efficacy in tissue regeneration [159,162].  
Regarding the production process, a detailed description must be given of all procedures related to 
product quality in the Standard Operating Procedures, as for conventional medical products. The 
purity, safety, functionality and identity criteria used for conventional drugs must be met. 
Development of techniques for cell identification within a mixed cell culture population and for 
follow-up of transplanted cells will also be essential to ascertain the potential in vivo invasive 
processes and to ensure biosafety [159]. The production process must occur in a highly aseptic 
environment with comprehensive controls of both raw materials and handlers; it has to be reproducible 
and validated. Facilities where products are handled, packaged and stored should be designed and 
organized according to the Good Manufacturing Practice for Pharmaceutical Manufacturers (G.M.P.) 
guidelines [163]. Production and distribution should be controlled by the relevant local or national 
authorities based on the International Conference on Harmonization of Pharmaceuticals for Human 
Use, which standardized the potential interpretations and applications of the corresponding 
recommendations [164]. It is of paramount importance to prevent potential contamination, both 
microbiological and by endotoxins, due to defects in environmental conditions, handlers, culture 
containers or raw materials, or cross contamination with other products prepared at the same 
production plant. The number of technical staff should be the minimum required and should be trained 
in hygiene measures required for manipulation in a clean room [159]. 
In summary, aspects to be regulated mainly include control of development, manufacturing and 
quality using release and stability tests; non-clinical aspects such as the need for studies on 
biodistribution, cell viability and proliferation, differentiation levels and rates, and duration of in vivo 
function; and clinical aspects such as special dose characteristics, stratification risk and specific 
pharmacovigilance and traceability issues [159-161]. 
Since new stem cell-based therapies develop very fast, the regulatory framework must also adapt, 
although legislation may be expected to change more slowly. 
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8. Concluding Remarks 
Stem cell therapy, regenerative medicine and tissue engineering emerge as innovative therapeutic 
strategies for a wide range of diseases, including burn injury. Stem cell therapy represents an 
interesting research field. Before we can offer this multidisciplinary promising treatment strategy 
clinically, preclinical studies are needed in order to satisfy safety concerns, improve efficiency of cell 
transplantation, and to design scaffolds or matrices by tissue engineering.  
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